Follow-up and management of recurrent Wilms' tumor

Urologic Clinics of North America

Volumn 30, Issue 4, 2003, Pages 869-879

  Firoozi, Farzeen ^a   Kogan, Barry A ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; THIOTEPA; VASCULOTROPIN; VINCRISTINE;

AUTOTRANSPLANTATION; AZOOSPERMIA; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARDIOMYOPATHY; CARDIOTOXICITY; CHROMOSOME 11P; CHROMOSOME 16Q; CHROMOSOME 1P; CLEAR CELL SARCOMA; CONGESTIVE HEART FAILURE; DRUG MEGADOSE; FOLLOW UP; GENE EXPRESSION; GONADAL DISEASE; HEART FUNCTION; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; LABORATORY TEST; LIVER TOXICITY; LUNG FUNCTION; LUNG TOXICITY; METASTASIS; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL FUNCTION; NEPHRECTOMY; NEPHROBLASTOMA; NEPHROTOXICITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; REVIEW; RHABDOID TUMOR; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0344874615     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(03)00052-1     Document Type: Review

References (63)

1. Neville HL, Ritchey ML. Wilms' tumor. Overview of National Wilms' Tumor Study Group results. Urol Clin North Am 2000;27:435-42.
2. D'Angio GJ, Evans AE, Breslow N, et al. The treatment of Wilms' tumor: results of the National Wilms' Tumor Study. Cancer 1976;38:633-46.
3. D'Angio GJ, Evans A, Breslow N, et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer 1981;47:2302-11.
4. D'Angio GJ, Breslow N, Beckwith JB, et al. Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer 1989;64:349-60.
5. Green DM, Breslow NE, Beckwith JB, et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1998;16:3744-51.
6. Green DM, Breslow NE, Beckwith JB, et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1998;16:237-45.
7. Wu HS, Snyder H. Advances in pediatric urology. AUA Update Series 2002;22:26-7.
8. Green DM, Grigoriev YA, Nan B, et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 2001;19:1926-34.
9. Sorensen K, Levitt G, Sebag-Montefiore D, et al. Cardiac function in Wilms' tumor survivors. J Clin Oncol 1995;13:1526-55.
10. Pinkel D, Camitta B, Kun L, et al. Doxirubicin cardiomyopathy in children with left-sided Wilms' tumor. Med Pediatr Oncol 1982;10:483-8.
11. Benoist MR, Lemerle J, Jean R, et al. Effects of pulmonary function of whole lung irradiation for Wilm's tumour in children. Thorax 1982;37:175-80.
12. Green DM, Finklestein JZ, Tefft ME, et al. Diffuse interstitial pneumonitis after pulmonary irradiation for metastatic Wilms' tumor. A report from the National Wilms' Tumor Study. Cancer 1989;63:450-3.
13. Ritchey ML, Green DM, Thomas PR, et al. Renal failure in Wilms' tumor patients: a report from the National Wilms' Tumor Study Group. Med Pediatr Oncol 1996;26:75-80.
14. 2 of ifosfamide. Cancer Chemother Pharmacol 1994;34:431-3.
15. Welch TR, McAdams AJ. Focal glomerulosclerosis as a late sequela of Wilms tumor. J Pediatr 1986;108:105-9.
16. Green DM, Norkool P, Breslow NE, et al. Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules: a report from the National Wilms' Tumor Study. J Clin Oncol 1990;8:1525-30.
17. Bisogno G, de Kraker J, Weirich A, et al. Venoocclusive disease of the liver in children treated for Wilms tumor. Med Pediatr Oncol 1997;29:245-51.
18. Shalet SM, Beardwell CG, Jacobs HS, et al. Testicular function following irradiation of the human prepubertal testis. Clin Endocrinol (Oxf) 1978;9:483-90.
19. Shalet SM, Beardwell CG, Jones PH, et al. Ovarian failure following abdominal irradiation in childhood. Br J Cancer 1976;33:655-8.
20. Stillman RJ, Schinfeld JS, Schiff I, et al. Ovarian failure in long-term survivors of childhood malignancy. Am J Obstet Gynecol 1981;139:62-6.
21. Blatt J. Pregnancy outcome in long-term survivors of childhood cancer. Med Pediatr Oncol 1999;33:29-33.
22. Byrne J, Mulvihill JJ, Connelly RR, et al. Reproductive problems and birth defects in survivors of Wilms' tumor and their relatives. Med Pediatr Oncol 1988;16:233-40.
23. Green DM, Peabody EM, Nan B, et al. Pregnancy outcome after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 2002;20:2506-13.
24. Hogeboom CJ, Grosser SC, Guthrie KA, et al. Stature loss following treatment for Wilms tumor. Med Pediatr Oncol 2001;36:295-304.
25. Ludin A, Macklis RM. Radiotherapy for pediatric genitourinary tumors. Its role and long-term consequences. Urol Clin North Am 2000;27:553-62.
26. Othman F, Guo CY, Webber C, et al. Osteopenia in survivors of Wilms tumor. Int J Oncol 2002;20:827-33.
27. Paulino AC, Wen BC, Brown CK, et al. Late effects in children treated with radiation therapy for Wilms' tumor. Int J Radiat Oncol Biol Phys 2000;46:1239-46.
28. Wallace WH, Shalet SM, Morris-Jones PH, et al. Effect of abdominal irradiation on growth in boys treated for a Wilms' tumor. Med Pediatr Oncol 1990;18:441-6.
29. Breslow NE, Takashima JR, Whitton JA, et al. Second malignant neoplasms following treatment for Wilm's tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1995;13:1851-9.
30. Carli M, Frascella E, Tournade MF, et al. Second malignant neoplasms in patients treated on SIOP Wilms tumour studies and trials 1, 2, 5, and 6. Med Pediatr Oncol 1997;29:239-44.
31. Cherullo EE, Ross JH, Kay R, et al. Renal neoplasms in adult survivors of childhood Wilms' tumor. J Urol 2001;165:2016-7.
32. Green DM, Breslow NE, et al. Wilms' tumor. In. Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 3rd edition. Philadelphia: Lippincott-Raven; 1997. p. 733-59.
33. Blann AD, Li JL, Li C, et al. Increased serum VEGF in 13 children with Wilms' tumour falls after surgery but rising levels predict poor prognosis. Cancer Lett 2001;173:183-6.
34. Rebhandl W, Handisurya A, Memaran N, et al. Expression of cytokeratin-18-related tissue polypeptide-specific (TPS) antigen in Wilms tumor. Med Pediatr Oncol 2001;37:357-64.
35. Coppes MJ. Serum biological markers and paraneoplastic syndromes in Wilms tumor, Med Pediatr Oncol 1993;21:213-21.
36. Grundy PE, Telzerow PE, Breslow N, et al. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome, Cancer Res 1994;54:2331-3.
37. Lu YJ, Hing S, Williams R, et al. Chromosome 1q expression profiling and relapse in Wilms' tumour. Lancet 2002;360:385-6.
38. D'Angio GJ, Rosenberg H, Sharples K, et al. Position paper: imaging methods for primary renal tumors of childhood: costs versus benefits. Med Pediatr Oncol 1993;21:205-12.
39. Clericuzio CL, Johnson C. Screening for Wilms tumor in high-risk individuals. Hematol Oncol Clin North Am 1995;9:1253-65.
40. Grundy P, Breslow N, Green DM, et al. Prognostic factors for children with recurrent Wilms' tumor: results from the second and third National Wilms' Tumor Study. J Clin Oncol 1989;7:638-47.
41. Sutow WW, Breslow NE, Palmer NF, et al. Prognosis in children with Wilms' tumor metastases prior to or following primary treatment: results from the first National Wilms' Tumor Study (NWTS-I). Am J Clin Oncol 1982;5:339-47.
42. Coppes MJ, Arnold M, Beckwith JB, et al. Factors affecting the risk of contralateral Wilms tumor development: a report from the National Wilms Tumor Study Group. Cancer 1999;85:1616-25.
43. Green DM, Breslow NE, Ii Y, et al. The role of surgical excision in the management of relapsed Wilms' tumor patients with pulmonary metastases: a report from the National Wilms' Tumor Study. J Pediatr Surg 1991;26:728-33.
44. Paulino AC. Relapsed Wilms tumor: is there a. role for radiation therapy? Am J Clin Oncol 2001;24:408-13.
45. Carpenter PA, White L, McCowage GB, et al. A dose-intensive, cyclophosphamide- based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group. Cancer 1997;80:489-96.
46. de Camargo B, Melaragno R, Saba e Silva N, et al. Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: experience of the Brazilian Wilms' Tumor Study Group. Med Pediatr Oncol 1994;22:258-60.
47. Dome JS, Liu T, Krasin M, et al. Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol 2002;24:192-8.
48. Egeler RM, Wolff JE, Anderson RA, et al. Long-term complications and post-treatment follow-up of patients with Wilms' tumor. Semin Urol Oncol 1999;17:55-61.
49. Finklestein JZ, Hittle RE, Hammond GD. Evaluation of a high dose cyclophosphamide regimen in childhood tumors. Cancer 1969;23:1239-42.
50. Garaventa A, Hartmann O, Bernard JL, et al. Autologous bone marrow transplantation for pediatric Wilms' tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry. Med Pediatr Oncol 1994;22:11-4.
51. Green DM. The treatment of advanced or recurrent malignant genitourinary tumors in children. Cancer 1987;60:602-11.
52. Groot-Loonen JJ, Pinkerton CR, Morris-Jones PH, et al. How curable is relapsed Wilms' tumour? The United Kingdom Children's Cancer Study Group. Arch Dis Child 1990;65:968-70.
53. Kamalakar P, Freeman AI, Higby DJ, et al. Clinical response and toxicity with cis-dichlorodiammineplatinum(II) in children. Cancer Treat Rep 1977;61:835-9.
54. Kung F, Hayes FA, Krischer J, et al. Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group. Invest New Drugs 1988;6:31-6.
55. Kung FH, Desai SJ, Dickerman JD, et al. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol 1995;17:265-9.
56. Kung FH, Pratt CB, Vega RA, et al. Ifosfamide/ etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer 1993;71:1898-1903.
57. Pein F, Michon J, Valteau-Couanet D, et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. J Clin Oncol 1998;16:3295-3301.
58. Pein F, Pinkerton R, Tournade MF, et al. Etoposide in relapsed or refractory Wilms' tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol 1993;11:1478-81.
59. Pein F, Tournade MF, Zucker JM, et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor-a phase II study by the French Society of Pediatric Oncology. J Clin Oncol 1994;12:931-6.
60. Pinkerton CR, Groot-Loonen JJ, Morris-Jones PH, et al. Response rates in relapsed Wilms' tumor. A need for new effective agents. Cancer 1991;67:567-71.
61. van Hoff J, Grier HE, Douglass EC, et al. Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity. Cancer 1995;75:2966-70.
62. Miser JS, Tournade MF. The management of relapsed Wilms Tumor. Hematol Oncol Clin North Am 1995;9:1287-1302.
63. Warkentin JA, Brochstein SE, Strandjord SE, et al. High-dose therapy followed by autologous rescue for recurrent Wilms' tumor. Presented at the Proceedings of the American Society of Oncology, 1993.